Effect of ofatumumab versus placebo in relapsing multiple sclerosis patients from Japan and Russia: Phase 2 APOLITOS study.

Jun-Ichi KiraJin NakaharaDenis V SazonovTakayoshi KurosawaIsao TsumiyamaRoman WilliMartin ZalesakRatnakar PingiliDieter A HäringKrishnan RamanathanBernd C KieseierMartin MerschhemkeWendy SuTakahiko Saida

Published in: Multiple sclerosis (Houndmills, Basingstoke, England) (2021)

Ofatumumab demonstrated superior efficacy versus placebo, with sustained effect through 48 weeks in RMS patients from Japan/Russia. Switching to ofatumumab after 24 weeks led to rapid radiological and clinical benefits. Safety findings were consistent with pivotal trials.

Keyphrases

multiple sclerosis
end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
prognostic factors
clinical trial
systemic lupus erythematosus
open label